Funding for this research was provided by:
Received: 16 November 2018
Accepted: 28 October 2019
First Online: 12 November 2019
Ethics approval and consent to participate
: The three trials used in this study were registered with ExternalRef removed, numbers NCT02456740, NCT02483585 and NCT02066415 as previously reported. For each of the study sites the final study protocol was approved by an Institutional Review Board/Independent Ethics Committee. Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: GLDT was an employee of Amgen at the time of the study. RBL is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the NIH: 2PO1 AG003949 (Program Director), 5 U10 NS077308 (PI), 1RO1 AG042595 (Investigator), RO1 NS082432 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of <i>Neurology</i> and as senior advisor to <i>Headache</i>. He has reviewed for the National Institute on Aging and National Institute of Neurological Disorders and Stroke; holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from <i>Wolff’s Headache</i>, 8th Edition, Oxford Press University, 2009, Wiley and Informa. AH was an employee of BresMed Health Solutions when the study was conducted, which has received consulting fees from Amgen. JP, SS and GV are employed by Amgen and have stock in Amgen.